We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.51 | 1.54% | 33.57 | 33.53 | 34.04 | 33.61 | 33.33 | 33.33 | 15,440 | 21:30:00 |
From May 2019 to May 2024
By Colin Kellaher
Pfizer Inc. and Merck KGaA's EMD Serono unit on Friday said they are ending a Phase III study of the immunotherapy Bavencio in head and neck cancer because it was unlikely to meet its primary endpoint.
The companies said the study evaluating Bavencio in addition to chemoradiotherapy, the standard of care, in patients with untreated locally advanced squamous cell carcinoma of the head and neck, was unlikely to show a statistically significant improvement in progression-free survival based on a preplanned interim analysis.
Pfizer and EMD said they have accepted the recommendation of the study's independent data monitoring committee to terminate the trial.
Germany's Merck and New York-based Pfizer formed a strategic alliance in 2014 to jointly develop and commercialize Bavencio. The drug is currently approved in 50 countries for patients with the skin cancer Merkel cell carcinoma.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 13, 2020 09:11 ET (13:11 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
